- Tetra Bio-Pharma Inc. (TBP) has shared a regulatory status update on the THC-based REDUVO new drug submission
- In December 2020, the company submitted its first new drug submission for its REDUVO soft gel capsules
- REDUVO is used to treat chemotherapy-induced nausea and vomiting. It is also used to treat weight loss and severe nausea in people living with HIV infection
- Tetra just received a clarification request from Health Canada regarding the product labels and will respond shortly
- Tetra Bio-Pharma Inc. (TBP) is up 66.67 per cent, trading at $0.02 per share as of 3:06 p.m. EST
Cannabinoid-derived drug developer, Tetra Bio-Pharma Inc. (TBP), has shared a regulatory status update on the REDUVO new drug submission.
Tetra, using a U.S. Food and Drug Administration and a Health Canada-cleared clinical program, works on bringing novel prescription drugs and treatments to patients and their healthcare providers.
The company’s scientific approach has enabled it to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology.
Back in December 2020, the company submitted its first new drug submission for its REDUVO soft gel capsules to Health Canada in order to obtain approval and a drug identification number for the capsules.
REDUVO is used to treat chemotherapy-induced nausea and vomiting. It is also used to treat weight loss and severe nausea in people living with HIV infection. The active pharmaceutical ingredient in REDUVO is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis.
According to the company, REDUVO’s five-year cumulative gross sales are expected to reach $121 million.
Earlier this week, Tetra received a clarification request from Health Canada regarding the product labels. The company will be submitting the expected response to Health Canada within the allowed timeframe.
Tetra Bio-Pharma Inc. (TBP) is up 66.67 per cent, trading at $0.02 per share as of 3:06 p.m. EST.
